摘要:
The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.
摘要:
Novel and known bicyclic 4-aralkylaminopyrimidine derivatives of formula (I) wherein A is a benzene or imidazole ring; B is a benzene, tetralin, indane or 2-oxindole ring R is (C.sub.1 -C.sub.4)perfluoroalkyl, phenyl, phenyl-(C.sub.1 -C.sub.4)alkyl, hydroxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.2 -C.sub.4)acyloxy-(C.sub.1 -C.sub.4)alkyl, halobenzoyloxy-(C.sub.1 -C.sub.4)alkyl, carboxy, carbamoyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, cyano, (C.sub.1 -C.sub.4)alkylcarbonyl, carboxy-(C.sub.1 -C.sub.4)alkyl, carbamoyl-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.4)alkyl, halo-(C.sub.1 -C.sub.4)alkyl, amino-(C.sub.1 -C.sub.4)alkyl, mono- or di-(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkyl, sulfo-(C.sub.1 -C.sub.4)alkyl or sulfamido-(C.sub.1 -C.sub.4)alkyl; each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or --NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6, which may be the same or different, is H or C.sub.1 -C.sub.4 alkyl; each of R.sub.3 and R.sub.4, which may the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof, are tyrosine kinase inhibitors. ##STR1##
摘要:
Novel bicyclic condensed pyrimidine compounds having general formula (I) ##STR1## wherein X is --CH.sub.2 --, --NH--(CH.sub.2).sub.n --, --O--(CH.sub.2).sub.n -- or --S--(CH.sub.2).sub.n -- in which n is zero or 1; A is a 4,5-fused imidazole ring N-substituted by R.sub.3 which is hydrogen, C.sub.1 -C.sub.4 alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by R.sub.4 which is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6 independently is H or C.sub.1 -C.sub.4 alkyl; B is a bicyclic ring chosen from tetralin, indane and 2-oxindole; each of R.sub.1 and R.sub.2 independently is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof.
摘要:
The present invention provides the new use in the manufacture of a medicament for use in the treatment of amyloidosis of an anthracycline of formula A: wherein R1, R2, R3 and X are appropriate substituents. Novel compounds of the formula A, processes for their production and pharmaceutical compositions containing them are also described.
摘要:
Arylidene and heteroarylidene oxindole derivatives of formula (I) ##STR1## wherein, subject to provisos, Y is a bicyclic ring system chosen from naphthalene, tetralin, quinoline and isoquinoline;R is hydrogen or an oxo (.dbd.O) group when Y is tetralin; orR is hydrogen when Y is naphthalene, quinoline or isoquinoline;each of R.sup.1 and R.sup.2 independently is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl;m is zero, 1 or 2;n is zero, 1, 2 or 3;each of R.sup.3 and R.sup.4 independently is hydrogen, halogen, cyano, C.sub.1 -C.sub.6 alkyl, carboxy, nitro or --NR.sup.6 R.sup.7 in which each of R.sup.6 and R.sup.7 independently is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and their pharmaceutically acceptable salts, which are useful as tyrosine kinase inhibitors.